GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (OTCPK:OCTHF) » Definitions » 3-Year EPS without NRI Growth Rate

Oxford Cannabinoid Technologies Holdings (Oxford Cannabinoid Technologies Holdings) 3-Year EPS without NRI Growth Rate : -26.00% (As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings 3-Year EPS without NRI Growth Rate?

Oxford Cannabinoid Technologies Holdings's EPS without NRI for the six months ended in Oct. 2023 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Oxford Cannabinoid Technologies Holdings was -26.00% per year. The lowest was -26.00% per year. And the median was -26.00% per year.


Competitive Comparison of Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate falls into.



Oxford Cannabinoid Technologies Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Oxford Cannabinoid Technologies Holdings  (OTCPK:OCTHF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Oxford Cannabinoid Technologies Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (Oxford Cannabinoid Technologies Holdings) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (Oxford Cannabinoid Technologies Holdings) Headlines

No Headlines